Items where SHU Author is "Lawson, Kim"
|Up a level|
Number of items: 23.
LAWSON, Kim (2016). Potential drug therapies for the treatment of fibromyalgia. Expert opinion on investigational drugs, 1-11.
LAWSON, Kim (2017). Emerging pharmacological strategies for the treatment of fibromyalgia. World Journal of Pharmacology, 6 (1), 1-10.
LAWSON, Kim (2014). Clinical trials for patients with fibromyalgia syndrome. Clinical & Experimental Pharmacology, 04 (05).
MARTELLI, A., TESTAI, L., BRESCHI, M.C., LAWSON, Kim, MCKAY, Neil, MICELI, F., TAGLIALATELA, M. and CALDERONE, V. (2013). Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. Pharmacological Research, 70 (1), 27-34.
BEARD, S M, ROSKELL, N, LE, T K, ZHAO, Y, COLEMAN, A, ANG, D and LAWSON, Kim (2011). Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. Journal of medical economics.
VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna (2011). Phasic activity of urinary bladder smooth muscle in the streptozotocin-induced diabetic rat: effect of potassium channel modulators. European Journal of Pharmacology, 660 (2-3), 431-437.
VAHABI, B., MCKAY, N. G., LAWSON, K. and SELLERS, D. J. (2010). The role of c-kit-positive interstitial cells in mediating phasic contractions of bladder strips from streptozotocin-induced diabetic rats. BJU International.
PUTTINI, P. Sarzi, HÄUSER, W., LAWSON, Kim and SPROTT, H. (2009). 11 Topical Seminar Summary: FIBROMYALGIA SYNDROME. European Journal of Pain, 13, S5-S6.
VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna (2009). Cholinergic modulation of spontaneous activity in bladder strips from the diabetic rat : effect of the mucosa. European Eurology Supplements, 8 (4), p. 177.
LAWSON, K. (2009). Pregabalin and Fibromyalgia Syndrome: A Treatment Option. Clinical Medicine: Therapeutics, 1, 809-824.
LAWSON, K., SHAWCROSS, E. and RAPHAEL, J. H. (2008). Function of Potassium Channels in Blood Mononuclear Cells of Patients with Fibromyalgia. Journal of pain management, 1 (3), 289-293.
VAHABI, B., MCKAY, Neil, LAWSON, Kim and SELLERS, Donna (2008). Identification of C-Kit positive cells in rat urinary bladder and characterization of their functional role in spontaneous activity in control and diabetic bladders. European Eurology Supplements, 7 (3), p. 181.
SELLERS, Donna, MCKAY, Neil and LAWSON, Kim (2008). Inhibitory effect of cromakalim on muscarinic receptor-stimulated spontaneous activity in diabetic rat bladder. Fundamental & Clinical Pharmacology, 22 (Suppl), p34.
LAWSON, K., SHAWCROSS, E. and RAPHAEL, J. H. (2008). Insensitivity of Lymphocytes of Patients with Neuropathic Pain Conditions to K+Channel Blockers. Journal of pain management, 1 (1), 43-48.
LAWSON, K. (2008). Pharmacological treatments of fibromyalgia: Do complex conditions need complex therapies? Drug Discovery Today, 13 (7-8), 333-340.
MCKAY, Neil, KIRBY, R W and LAWSON, Kim (2008). Rubidium efflux as a tool for the pharmacological characterisation of compounds with BK channel opening properties. In: LIPPIAT, Jonathan D, (ed.) Potassium channels : methods and protocols. Methods in Molecular Biology (491). Humana Press, 267-277.
LAWSON, K. (2008). Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatric disease and treatment, 4 (6), 1059-1071.
LAWSON, Kim (2007). Are complex therapies required as pharmacological treatments of fibromyalgia? Future Rheumatology, 2 (6), 599-605.
LAWSON, Kim (2006). Emerging pharmacological therapies for fibromyalgia. Current Opinion in Investigational Drugs, 7 (7), 631-636.
LAWSON, Kim (2006). Potassium channels as targets for the management of pain. Central Nervous System Agents in Medicinal Chemistry, 6 (2), 119-128.
LAWSON, K. and MCKAY, N. (2006). Modulation of potassium channels as a therapeutic approach. Current Pharmaceutical Design, 12 (4), 459-470.
LAWSON, Kim (2002). Tricyclic antidepressants and fibromyalgia: what is the mechanism of action? Expert opinion on investigational drugs, 11 (10), 1437-1445.
LAWSON, Kim and DUNNE, Mark J. (2001). Peripheral channelopathies as targets for potassium channel openers. Expert opinion on investigational drugs, 10 (7), 1345-1359.